Literature DB >> 15553234

Use of loperamide as a phenotypic probe of mdr1a status in CF-1 mice.

J Cory Kalvass1, Candace L Graff, Gary M Pollack.   

Abstract

PURPOSE: A subpopulation of the CF-1 mouse strain (approximately 25%) lacks P-gp expression, and consequently, increased brain penetration of many substrates is observed in these animals. Mice lacking the mdr1a gene represent an important research tool to study the potential effects of P-gp on CNS substrate disposition.
METHODS: Adult CF-1 mice were used in all experiments. Loperamide-induced antinociception was determined by the hotplate latency test at 0.25, 2, and 4 h post-dose. At the conclusion of the pharmacodynamic experiment(s), trunk blood and brain tissue were collected and analyzed by high-performance liquid chromatography-mass spectrometry (LC-MS/MS). Mice were also genotyped for their mdrla status via RT-PCR.
RESULTS: All mice with three consecutive effects of maximum hotplate latency (60 s) showed considerable opioid-like behavior in addition to antinociception. Mice without three consecutive effects of maximum hotplate latency (< or = 30 s) showed no opioid-like behavior. The loperamide brain-to-serum ratio in mice identified as P-gp-deficient was 65-fold higher compared to the P-gp-competent animals (10.1 +/- 1.0 vs. 0.155 +/- 0.018). All animals identified as phenotypically P-gp-competent based on the hotplate assay evidenced the mdrla(+/+) genotype.
CONCLUSION: This assay appears to offer a rapid and unambiguous measure via a relatively non-invasive, simple technique to identify P-gp status in the CF-1 subpopulation of mice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15553234     DOI: 10.1023/b:pham.0000045241.26925.8b

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  15 in total

Review 1.  Multidrug resistance: molecular mechanisms and clinical relevance.

Authors:  V Ling
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

Review 2.  Blood-brain barrier efflux transport.

Authors:  Pamela L Golden; Gary M Pollack
Journal:  J Pharm Sci       Date:  2003-09       Impact factor: 3.534

Review 3.  P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins.

Authors:  P F Juranka; R L Zastawny; V Ling
Journal:  FASEB J       Date:  1989-12       Impact factor: 5.191

4.  Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism.

Authors:  D R Umbenhauer; G R Lankas; T R Pippert; L D Wise; M E Cartwright; S J Hall; C M Beare
Journal:  Toxicol Appl Pharmacol       Date:  1997-09       Impact factor: 4.219

5.  P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity.

Authors:  G R Lankas; M E Cartwright; D Umbenhauer
Journal:  Toxicol Appl Pharmacol       Date:  1997-04       Impact factor: 4.219

6.  Increased drug delivery to the brain by P-glycoprotein inhibition.

Authors:  A J Sadeque; C Wandel; H He; S Shah; A J Wood
Journal:  Clin Pharmacol Ther       Date:  2000-09       Impact factor: 6.875

7.  Antagonism of the morphine-induced Straub tail reaction by kappa-opioid receptor activation in mice.

Authors:  M Narita; T Suzuki; M Misawa; H Nagase
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

Authors:  A H Schinkel; E Wagenaar; C A Mol; L van Deemter
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

Review 9.  Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals.

Authors:  P Borst; A H Schinkel; J J Smit; E Wagenaar; L Van Deemter; A J Smith; E W Eijdems; F Baas; G J Zaman
Journal:  Pharmacol Ther       Date:  1993-11       Impact factor: 12.310

10.  No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects.

Authors:  Christiane Pauli-Magnus; John Feiner; Claire Brett; Emil Lin; Deanna L Kroetz
Journal:  Clin Pharmacol Ther       Date:  2003-11       Impact factor: 6.875

View more
  8 in total

1.  Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition.

Authors:  J Cory Kalvass; Gary M Pollack
Journal:  Pharm Res       Date:  2006-12-27       Impact factor: 4.200

2.  Compartmental models for apical efflux by P-glycoprotein--part 1: evaluation of model complexity.

Authors:  Swati Nagar; Jalia Tucker; Erica A Weiskircher; Siddhartha Bhoopathy; Ismael J Hidalgo; Ken Korzekwa
Journal:  Pharm Res       Date:  2013-09-10       Impact factor: 4.200

3.  A Conformationally Gated Model of Methadone and Loperamide Transport by P-Glycoprotein.

Authors:  Morgan E Gibbs; Laura A Wilt; Kaitlyn V Ledwitch; Arthur G Roberts
Journal:  J Pharm Sci       Date:  2018-02-28       Impact factor: 3.534

Review 4.  Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective.

Authors:  Kunal S Taskar; Xinning Yang; Sibylle Neuhoff; Mitesh Patel; Kenta Yoshida; Mary F Paine; Kim L R Brouwer; Xiaoyan Chu; Yuichi Sugiyama; Jack Cook; Joseph W Polli; Imad Hanna; Yurong Lai; Maciej Zamek-Gliszczynski
Journal:  Clin Pharmacol Ther       Date:  2022-06-22       Impact factor: 6.903

5.  Assessment of blood-brain barrier permeability using the in situ mouse brain perfusion technique.

Authors:  Rong Zhao; J Cory Kalvass; Gary M Pollack
Journal:  Pharm Res       Date:  2009-04-22       Impact factor: 4.200

6.  Evaluation of the P-glycoprotein (Abcb1) affinity status of a series of morphine analogs: comparative study with meperidine analogs to identify opioids with minimal P-glycoprotein interactions.

Authors:  Hazem E Hassan; Susan L Mercer; Christopher W Cunningham; Andrew Coop; Natalie D Eddington
Journal:  Int J Pharm       Date:  2009-04-05       Impact factor: 5.875

7.  Blood-brain and retinal barriers show dissimilar ABC transporter impacts and concealed effect of P-glycoprotein on a novel verapamil influx carrier.

Authors:  Hélène Chapy; Bruno Saubaméa; Nicolas Tournier; Fanchon Bourasset; Francine Behar-Cohen; Xavier Declèves; Jean-Michel Scherrmann; Salvatore Cisternino
Journal:  Br J Pharmacol       Date:  2016-01-15       Impact factor: 8.739

8.  Liquid chromatography-tandem mass spectrometry for analysis of intestinal permeability of loperamide in physiological buffer.

Authors:  Miriam S Rubelt; Salah Amasheh; Thomas Grobosch; Christoph Stein
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.